Skadden represented JP Morgan as lead underwriter in the initial public offering of Dutch biotech company Prosensa Therapeutics BV, which debuted on Nasdaq on June 28. Prosensa develops antisense technology for therapies to treat muscular dystrophy.

BACK TO TOP